E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143

Li,Jibin; Wang,Xinling; Zhang,Yanshang; Zhang,Yan

doi:10.3892/etm.2016.3429

E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143

Authors:
- Jibin Li
- Xinling Wang
- Yanshang Zhang
- Yan Zhang
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China, Department of Orthopedics, Gongli Hospital of Pudong New Area, Shanghai 200135, P.R. China
Published online on: June 6, 2016 https://doi.org/10.3892/etm.2016.3429
Pages: 676-682
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is one of the most common gynecological cancers worldwide. Aberrant expression of E3 ubiquitin ligase isolated by differential display (EDD) has been detected in various types of tumor and has been demonstrated to have an important role in carcinogenesis, tumor growth and drug resistance. However, the role of EDD in cervical cancer and its underlying molecular mechanisms remains unknown. The present study aimed to investigate the role of EDD in the tumorigenicity of cervical cancer. EDD expression levels were measured using reverse transcription‑quantitative polymerase chain reaction and western blotting in SiHa, HeLa, CaSki, c‑41 and c‑33A cervical cancer cell lines and cervical cancer tissue specimens. A functional study was performed using cell proliferation, colony formation, cell apoptosis assays in vitro and tumor growth assays in vivo with EDD either overexpressed or silenced. In the present study, EDD expression levels were significantly upregulated in cervical cancer cell lines and tissue samples. EDD knockdown significantly inhibited colony formation, cell proliferation and tumor growth and accelerated cell apoptosis in the cervical cancer cell lines and tissue samples. Furthermore, microRNA (miR)‑143 expression levels were low in cervical cancer tissue samples and were negatively correlated with EDD expression. miR‑143 silencing eliminated the effect of EDD on cell proliferation, colony formation and cell apoptosis in the cervical cancer cells, which suggested that miR‑143 is critical for EDD‑mediated regulation of cervical cancer cell growth. The results of the present study indicated that EDD may promote cervical cancer growth in vivo and in vitro by targeting miR‑143. In conclusion, EDD may have an oncogenic role in cervical cancer and may serve as a potential therapeutic target for the treatment of patients with cervical cancer.

View Figures

View References

1	World Health Organization: Department of Reproductive Health and Research and Department of Chronic Diseases and Health Promotion: Comprehensive cervical cancer control: A guide to essential practice. World Health Organization. 2006.
2	World Health Organization: GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Lyon, France: International Agency for Research on Cancer. 2014.
3	Anorlu RI: Cervical cancer: The sub-Saharan African perspective. Reprod Health Matters. 16:41–49. 2008. View Article : Google Scholar : PubMed/NCBI
4	Rositch AF, Silver MI and Gravitt PE: Cervical cancer screening in older women: New evidence and knowledge gaps. PLoS Med. 11:e10015862014. View Article : Google Scholar : PubMed/NCBI
5	Noller K: Intraepithelial neoplasia of the lower genital tract (cervix, vulva): Etiology, screening, diagnostic techniques, management. Comprehensive Gynecology (5th). Mosby Elsevier. (Philadelphia, PA). 2007. View Article : Google Scholar
6	Tewari KS, Sill MW, Long HJ III, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, et al: Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 370:734–743. 2014. View Article : Google Scholar : PubMed/NCBI
7	Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, Rose PG and Covens AL: State of the science in cervical cancer: Where we are today and where we need to go. Cancer. 120:2282–2288. 2014. View Article : Google Scholar : PubMed/NCBI
8	Maguire R, Kotronoulas G, Simpson M and Paterson C: A systematic review of the supportive care needs of women living with and beyond cervical cancer. Gynecol Oncol. 136:478–490. 2015. View Article : Google Scholar : PubMed/NCBI
9	Schiffman M, Castle PE, Jeronimo J, Rodriguez AC and Wacholder S: Human papillomavirus and cervical cancer. Lancet. 370:890–907. 2007. View Article : Google Scholar : PubMed/NCBI
10	Chaturvedi AK: Beyond cervical cancer: Burden of other HPV-related cancers among men and women. J Adolesc Health. 46(Suppl): S20–S26. 2010. View Article : Google Scholar : PubMed/NCBI
11	Burd EM: Human papillomavirus and cervical cancer. Clin Microbiol Rev. 16:1–17. 2003. View Article : Google Scholar : PubMed/NCBI
12	Dasari S, Wudayagiri R and Valluru L: Cervical cancer: Biomarkers for diagnosis and treatment. Clin Chim Acta. 445:7–11. 2015. View Article : Google Scholar : PubMed/NCBI
13	Tasaki T, Mulder LC, Iwamatsu A, Lee MJ, Davydov IV, Varshavsky A, Muesing M and Kwon YT: A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons. Mol Cell Biol. 25:7120–7136. 2005. View Article : Google Scholar : PubMed/NCBI
14	Callaghan MJ, Russell AJ, Woollatt E, Sutherland GR, Sutherland RL and Watts CK: Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs. Oncogene. 17:3479–3491. 1998. View Article : Google Scholar : PubMed/NCBI
15	Henderson MJ, Russell AJ, Hird S, Muñoz M, Clancy JL, Lehrbach GM, Calanni ST, Jans DA, Sutherland RL and Watts CK: EDD, the human hyperplastic discs protein, has a role in progesterone receptor coactivation and potential involvement in DNA damage response. J Biol Chem. 277:26468–26478. 2002. View Article : Google Scholar : PubMed/NCBI
16	Beaudenon SL, Huacani MR, Wang G, McDonnell DP and Huibregtse JM: Rsp5 ubiquitin-protein ligase mediates DNA damage-induced degradation of the large subunit of RNA polymerase II in Saccharomyces cerevisiae. Mol Cell Biol. 19:6972–6979. 1999. View Article : Google Scholar : PubMed/NCBI
17	Kornitzer D and Ciechanover A: Modes of regulation of ubiquitin-mediated protein degradation. J Cell Physiol. 182:1–11. 2000. View Article : Google Scholar : PubMed/NCBI
18	Connor MK and Seth A: A central role for the ring finger protein RNF11 in ubiquitin-mediated proteolysis via interactions with E2s and E3s. Oncogene. 23:2089–2095. 2004. View Article : Google Scholar : PubMed/NCBI
19	Ang XL and Harper Wade J: SCF-mediated protein degradation and cell cycle control. Oncogene. 24:2860–2870. 2005. View Article : Google Scholar : PubMed/NCBI
20	Vidhyasekaran P: Ubiquitin-proteasome system-mediated protein degradation in defense signaling. PAMP Signals in Plant Innate Immunity. Springer. (The Netherlands). 409–430. 2014. View Article : Google Scholar
21	Benavides M, Chow-Tsang LF, Zhang J and Zhong H: The novel interaction between microspherule protein Msp58 and ubiquitin E3 ligase EDD regulates cell cycle progression. Biochim Biophys Acta. 1833:21–32. 2013. View Article : Google Scholar : PubMed/NCBI
22	Ling S and Lin WC: EDD inhibits ATM-mediated phosphorylation of p53. J Biol Chem. 286:14972–14982. 2011. View Article : Google Scholar : PubMed/NCBI
23	Munoz MA, Saunders DN, Henderson MJ, Clancy JL, Russell AJ, Lehrbach G, Musgrove EA, Watts CK and Sutherland RL: The E3 ubiquitin ligase EDD regulates S-phase and G2/M DNA damage checkpoints. Cell Cycle. 6:3070–3077. 2007. View Article : Google Scholar : PubMed/NCBI
24	Smits VA: EDD induces cell cycle arrest by increasing p53 levels. Cell Cycle. 11:715–720. 2012. View Article : Google Scholar : PubMed/NCBI
25	McDonald WJ, Thomas LN, Koirala S and Too CK: Progestin-inducible EDD E3 ubiquitin ligase binds to α4 phosphoprotein to regulate ubiquitination and degradation of protein phosphatase PP2Ac. Mol Cell Endocrinol. 382:254–261. 2014. View Article : Google Scholar : PubMed/NCBI
26	Chen HW, Yang CC, Hsieh CL, Liu H, Lee SC and Tan BC: A functional genomic approach reveals the transcriptional role of EDD in the expression and function of angiogenesis regulator ACVRL1. Biochim Biophys Acta. 1829:1309–1319. 2013. View Article : Google Scholar : PubMed/NCBI
27	Su H, Meng S, Lu Y, Trombly MI, Chen J, Lin C, Turk A and Wang X: Mammalian hyperplastic discs homolog EDD regulates miRNA-mediated gene silencing. Mol Cell. 43:97–109. 2011. View Article : Google Scholar : PubMed/NCBI
28	Bethard JR, Zheng H, Roberts L and Eblen ST: Identification of phosphorylation sites on the E3 ubiquitin ligase UBR5/EDD. J Proteomics. 75:603–609. 2011. View Article : Google Scholar : PubMed/NCBI
29	Henderson MJ, Munoz MA, Saunders DN, Clancy JL, Russell AJ, Williams B, Pappin D, Khanna KK, Jackson SP, Sutherland RL and Watts CK: EDD mediates DNA damage-induced activation of CHK2. J Biol Chem. 281:39990–40000. 2006. View Article : Google Scholar : PubMed/NCBI
30	Gwinn D and Sweet-Cordero EA: The phosphatase PP2A links glutamine to the tumor suppressor p53. Mol Cell. 50:157–158. 2013. View Article : Google Scholar : PubMed/NCBI
31	Clancy JL, Henderson MJ, Russell AJ, Anderson DW, Bova RJ, Campbell IG, Choong DY, Macdonald GA, Mann GJ, Nolan T, et al: EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene. 22:5070–5081. 2003. View Article : Google Scholar : PubMed/NCBI
32	Fuja TJ, Lin F, Osann KE and Bryant PJ: Somatic mutations and altered expression of the candidate tumor suppressors CSNK1ε, DLG1, and EDD/hHYD in mammary ductal carcinoma. Cancer Res. 64:942–951. 2004. View Article : Google Scholar : PubMed/NCBI
33	O'Brien PM, Davies MJ, Scurry JP, Smith AN, Barton CA, Henderson MJ, Saunders DN, Gloss BS, Patterson KI, Clancy JL, et al: The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer. 98:1085–1093. 2008. View Article : Google Scholar : PubMed/NCBI
34	Kruzelock RP and Short W: Colorectal cancer therapeutics and the challenges of applied pharmacogenomics. Curr Probl Cancer. 31:315–366. 2007. View Article : Google Scholar : PubMed/NCBI
35	Yoon SY, Lee Y, Kim JH, Chung AS, Joo JH, Kim CN, Kim NS, Choe IS and Kim JW: Over-expression of human UREB1 in colorectal cancer: HECT domain of human UREB1 inhibits the activity of tumor suppressor p53 protein. Biochem Biophys Res Commun. 326:7–17. 2005. View Article : Google Scholar : PubMed/NCBI
36	Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, et al: EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer. Carcinogenesis. 35:1100–1109. 2014. View Article : Google Scholar : PubMed/NCBI
37	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
38	Bueno MJ, de Pérez Castro I and Malumbres M: Control of cell proliferation pathways by microRNAs. Cell Cycle. 7:3143–3148. 2008. View Article : Google Scholar : PubMed/NCBI
39	Conrad R, Barrier M and Ford LP: Role of miRNA and miRNA processing factors in development and disease. Birth Defects Res C Embryo Today. 78:107–117. 2006. View Article : Google Scholar : PubMed/NCBI
40	Schoolmeesters A, Eklund T, Leake D, Vermeulen A, Smith Q, Aldred Force S and Fedorov Y: Functional profiling reveals critical role for miRNA in differentiation of human mesenchymal stem cells. PLoS One. 4:e56052009. View Article : Google Scholar : PubMed/NCBI
41	Shantikumar S, Caporali A and Emanueli C: Role of miRNA in diabetes and its cardiovascular complications. Cardiovasc Res. 93:583–93. 2012. View Article : Google Scholar : PubMed/NCBI
42	Wang Y, Zhang X, Li H, Yu J and Ren X: The role of miRNA-29 family in cancer. Eur J Cell Biol. 92:123–128. 2013. View Article : Google Scholar : PubMed/NCBI
43	Williams AE, Perry MM, Moschos SA, Larner-Svensson HM and Lindsay MA: Role of miRNA-146a in the regulation of the innate immune response and cancer. Biochem Soc Trans. 36:1211–1215. 2008. View Article : Google Scholar : PubMed/NCBI
44	Zhang N, Su Y and Xu L: Targeting PKCε by miR-143 regulates cell apoptosis in lung cancer. FEBS Lett. 587:3661–3667. 2013. View Article : Google Scholar : PubMed/NCBI
45	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
46	Pham H, Rodriguez CE, Donald GW, Hertzer KM, Jung XS, Chang HH, Moro A, Reber HA, Hines OJ and Eibl G: miR-143 decreases COX-2 mRNA stability and expression in pancreatic cancer cells. Biochem Biophys Res Commun. 439:6–11. 2013. View Article : Google Scholar : PubMed/NCBI
47	Zhang X, Dong Y, Ti H, Zhao J, Wang Y, Li T and Zhang B: Down-regulation of miR-145 and miR-143 might be associated with DNA methyltransferase 3B overexpression and worse prognosis in endometrioid carcinomas. Hum Pathol. 44:2571–2580. 2013. View Article : Google Scholar : PubMed/NCBI
48	Wang LQ, Zhang Y, Yan H, Liu KJ and Zhang S: MicroRNA-373 functions as an oncogene and targets YOD1 gene in cervical cancer. Biochem Biophys Res Commun. 459:515–520. 2015. View Article : Google Scholar : PubMed/NCBI
49	Puerta-Gil P, García-Baquero R, Jia AY, Ocaña S, Alvarez-Múgica M, Alvarez-Ossorio JL, Cordon-Cardo C, Cava F and Sánchez-Carbayo M: miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 180:1808–1815. 2012. View Article : Google Scholar : PubMed/NCBI
50	Zhu H, Dougherty U, Joseph LJ, Robinson V, Wu J, Song Z, Mustafi R, Fichera A and Bissonnette M: 1068 EGFR and c-MYC suppress Mir-143 and Mir-145 in colonic tumorigenesis: Roles of G1 cell cycle regulators as miRNA targets. Gastroenterol. 136:A164–A165. 2009. View Article : Google Scholar
51	Cho WC: MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta. 1805:209–217. 2010.PubMed/NCBI
52	Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C and Zheng ZM: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
53	Tang T, Wong HK, Gu W, Yu MY, To KF, Wang CC, Wong YF, Cheung TH, Chung TK and Choy KW: MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol Oncol. 129:199–208. 2013. View Article : Google Scholar : PubMed/NCBI
54	Qian X, Yu J, Yin Y, He J, Wang L, Li Q, Zhang LQ, Li CY, Shi ZM, Xu Q, et al: MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers. Cell Cycle. 12:1385–1394. 2013. View Article : Google Scholar : PubMed/NCBI
55	Shepherd JH: Cervical and vulva cancer: changes in FIGO definitions of staging. Br J Obstet Gynaecol. 103:405–406. 1996. View Article : Google Scholar : PubMed/NCBI
56	Liu L, Yu X, Guo X, Tian Z, Su M, Long Y, Huang C, Zhou F, Liu M, Wu X and Wang X: miR-143 is downregulated in cervical cancer and promotes apoptosis and inhibits tumor formation by targeting Bcl-2. Mol Med Rep. 5:753–760. 2012.PubMed/NCBI
57	Hu CE, Liu YC, Zhang HD and Huang GJ: The RNA-binding protein PCBP2 facilitates gastric carcinoma growth by targeting miR-34a. Biochem Biophys Res Commun. 448:437–442. 2014. View Article : Google Scholar : PubMed/NCBI
58	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-^ΔΔCt method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
59	Guo G, Kang Q, Chen Q, Chen Z, Wang J, Tan L and Chen JL: High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene. FEBS. 588:1780–1786. 2014. View Article : Google Scholar
60	Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, McBryan T, Doyle B, McKay C, Oien KA, et al: Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell. 42:36–49. 2011. View Article : Google Scholar : PubMed/NCBI
61	Sala A, Bettuzzi S, Pucci S, Chayka O, Dews M and Thomas-Tikhonenko A: Regulation of CLU gene expression by oncogenes and epigenetic factors: Implications for tumorigenesis. Adv Cancer Res. 105:115–132. 2009. View Article : Google Scholar : PubMed/NCBI
62	Keyes WM, Pecoraro M, Aranda V, Vernersson-Lindahl E, Li W, Vogel H, Guo X, Garcia EL, Michurina TV, Enikolopov G, et al: ΔNp63α is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell. 8:164–176. 2011. View Article : Google Scholar : PubMed/NCBI
63	Couto SS, Cao M, Duarte PC, Banach-Petrosky W, Wang S, Romanienko P, Wu H, Cardiff RD, Abate-Shen C and Cunha GR: Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. Differentiation. 77:103–111. 2009. View Article : Google Scholar : PubMed/NCBI
64	Imanishi Y and Tahara H: Putative parathyroid tumor suppressor on 1p: Independent molecular mechanisms of tumorigenesis from 11q allelic loss. Am J Kidney Dis. 38(Suppl 1): S165–S167. 2001. View Article : Google Scholar : PubMed/NCBI
65	Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Têtu B, Bairati I and Bachvarov D: Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 5:438–453. 2011. View Article : Google Scholar : PubMed/NCBI